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i.org/1guidelines recommend combined isosorbide dinitrate (ISDN) and hydralazine to reduce
mortality and morbidity for African-Americans with symptomatic heart failure (HF) and
reduced ejection fraction, currently receiving optimal medical therapy (class I, level A).
Nitrates can alleviate HF symptoms, but continuous use is limited by tolerance. Hydralazine
may mitigate nitrate tolerance, and the ISDNehydralazine combination in the Vasodilators
in Heart Failure Trial (V-HeFT) I improved survival and exercise tolerance in men with
dilated cardiomyopathy or HF with reduced ejection fraction, most notably in self-identiﬁed
black participants. In the subsequent V-HeFT II, survival was greater with enalapril than
with ISDNehydralazine in the overall cohort, but mortality rate was similar in the enalapril
and ISDNehydralazine groups in the self-identiﬁed black patients. Consequently, in the
African-American Heart Failure Trial (A-HeFT) in self-identiﬁed black patients with
symptomatic HF, adding a ﬁxed-dose combination ISDNehydralazine to modern guideline-
based care improved outcomes versus placebo, including all-cause mortality, and led to early
trial termination. Hypertension underlies HF, especially in African-Americans; the A-HeFT
and its substudies demonstrated not only improvements in echocardiographic parameters,
morbidity, and mortality but also a decrease in hospitalizations, potentially affecting bur-
geoning HF health-care costs. Genetic characteristics may, therefore, determine response to
ISDNehydralazine, and the Genetic Risk Assessment in Heart Failure substudy demon-
strated important hypothesis-generating pharmacogenetic data.  2014 Elsevier Inc. All
rights reserved. (Am J Cardiol 2014;114:151e159)The 2013 American College of Cardiology Foundation
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0.1016/j.amjcard.2014.04.018IV heart failure (HF) and HF with reduced ejection fraction
(EF) who are currently receiving optimal medical therapy
with angiotensin-converting enzyme inhibitors and b
blockers (class I, level A).1 The guidelines also state that the
combination of ISDN and hydralazine can be useful to
reduce morbidity and mortality in patients with current or
previous symptomatic HF who are not able to take
angiotensin-converting enzyme inhibitors or angiotensin II
receptor blockers (class IIa, level B).1 Nevertheless,
African-Americans remain more likely than whites to
die from diseases of the heart (Figure 1),2,3 and many pa-
tients who may beneﬁt from ISDNehydralazine are not
receiving it. This review details the rationale for using
ISDNehydralazine in African-Americans with HF as dis-
cussed at a roundtable meeting of cardiologists in November
2012. As HF is the primary diagnosis in >1 million hos-
pitalizations annually and annual costs related to HF in the
United States exceed $40 billion, advances in the treatment
of HF would have signiﬁcant economic beneﬁts.1Rationale for the Study of Isosorbide Dinitrate and
Hydralazine in Patients With HF
Organic nitrates, including ISDN, activate the intracellular
enzyme soluble guanylyl cyclase and subsequently elevate
cyclic guanosine 30,50-monophosphate levels. The elevatedwww.ajconline.org
Figure 1. “Diseases of the heart” death rates by race and gender, 2010.3
152 The American Journal of Cardiology (www.ajconline.org)cyclic guanosine 30,50-monophosphate level leads to activa-
tion of cyclic guanosine 30,50-monophosphateedependent
protein kinase, which in turn mediates vasorelaxation by
phosphorylating proteins that regulate intracellular calcium
mobilization.4 However, within several hours of sustained
exposure, nitrates (including ISDN) lose efﬁcacy quickly as
tolerance develops,5e7 leading to marked attenuation of he-
modynamic effects.
Hydralazine prevents and reverses nitrate tolerance—
preserving its capacity to reduce venous pressure—probably
by reducing superoxide production in vascular tissues and
possibly also by scavenging reactive oxygen species to
mitigate both vascular tolerance and cross-tolerance.8e13
Nitric oxide (NO) is an endogenous vasodilator that also
directly affects the myocardium to modulate contractility,
diastolic distensibility, mitochondrial respiration, substrate
metabolism, ion channel function, cell growth (hypertro-
phy), and postinfarction remodeling.14e17 In the presence of
superoxide and other reactive oxygen species, NO is con-
verted to peroxynitrite, reducing its capacity to relax the
endothelium. Peroxynitrite itself can interact with proteins
and genes to damage the endothelium and elicit endothelial
dysfunction.16
Data from animal models18e23 and clinical studies24e26
suggest that correction of NO bioavailability and/or
signaling capacity or reduction in oxidative stress favorably
alters HF end points. This hypothesis was tested using the
combination of ISDN and hydralazine in patients with HF
and HF with reduced EF in the Vasodilators in Heart Failure
Trial (V-HeFT) I and V-HeFT II.27,28
Isosorbide Dinitrate and Hydralazine in Heart Failure
Compared with placebo, treatment with ISDN and hy-
dralazine reduced the relative risk of death by 36% after
3 years with minimal background therapy (digoxin and di-
uretics) in V-HeFT I.27 Furthermore, ISDN and hydralazine
improved survival in black or African-American patients,
although the effect was not signiﬁcant in white patients
(Figure 2).29 In V-HeFT II, treatment with ISDN and hy-
dralazine did not improve survival compared with enalap-
ril,28 although the effects on all-cause mortality were
equivalent to those of enalapril in black patients and inferior
to enalapril in white patients.29These ﬁndings led to the design of an outcomes study
with ﬁxed-dose (FD) ISDNehydralazine (BiDil; Arbor
Pharmaceuticals, Inc, Atlanta, Georgia) in self-identiﬁed
black patients.30 The African-American Heart Failure Trial
(A-HeFT) enrolled 1,050 patients with New York Heart
Association class III or IV HF receiving guideline-based
care, including b blockers, angiotensin-converting enzyme
inhibitors, and/or angiotensin II receptor blockers.24 The
primary outcome of A-HeFT was a composite score of
mortality, hospitalization, and quality of life (QOL), and the
clear survival beneﬁt of FD ISDNehydralazine over pla-
cebo led to termination of the study after 3 years (Figure 3).
With a median follow-up period of 10 months, FD
ISDNehydralazine in combination with neurohormonal
blockade reduced mortality by 43%.24 In addition, in A-
HeFT, adding FD ISDNehydralazine to standard therapy
decreased the number of hospitalizations and reduced length
of hospital stay compared with standard therapy alone.24,31
The relative risk of an HF-related hospitalization during
the ﬁrst 2 years of treatment was equal to placebo in V-
HeFT I and to enalapril in V-HeFT II.28,29 In A-HeFT,
improvements in functional parameters included EF, left
ventricular (LV) remodeling, and signiﬁcant reduction in B-
type natriuretic peptide (BNP).24,32 Additionally, based on
the Minnesota Living with Heart Failure questionnaire, pa-
tients in A-HeFT reported improved QOL with FD
ISDNehydralazine.24,33
The ﬁrst hospitalization for HF was a component of the
primary composite score in A-HeFT. With a mean follow-
up of 10 months (range 0 to 18), 130 patients (24.4%) in
the placebo group and 85 (16.4%) in the FD
ISDNehydralazine group (p ¼ 0.001) were hospitalized.24
Relative risk of ﬁrst HF hospitalization was reduced by
39% with FD ISDNehydralazine compared with placebo
(hazard ratio 0.61, 95% conﬁdence interval 0.46 to 0.80, p
<0.001; Figure 4).34 The treatment effect appeared early,
approximately 50 days after starting treatment, and
remained signiﬁcant throughout the study. A similar bene-
ﬁcial effect of FD ISDNehydralazine was observed in all
the subgroups analyzed, including age (< or >65 years),
gender, ischemic HF etiology, baseline blood pressure (BP;
systolic BP >126 mm Hg), presence of diabetes mellitus,
history of chronic renal insufﬁciency, and baseline medi-
cation usage. Nevertheless, race is a social construct and not
a physiologic concept and is an imprecise surrogate for
genetic-related differences among subjects. Results of
A-HeFT, therefore, will be clariﬁed with continued genetic-
based research, and clinicians should recognize the signiﬁ-
cant heterogeneity among prespeciﬁed groups, with perhaps
greater genetic differences within than between certain
racial or ethnic groups.
Combined treatment with ISDN and hydralazine has
shown good tolerability. In V-HeFT I, discontinuation rates
were identical for ISDN and hydralazine versus placebo
(22% in both groups).27 The main adverse events leading to
discontinuation of ISDN and hydralazine were headache
(12%), dizziness (6%), gastrointestinal effects (4%), and
nervous system effects (4%); 3 patients (2%) discontinued
because of arthralgia and 3 because of possible lupus.27
Headache was the only adverse event observed more
frequently with ISDN and hydralazine than with enalapril in
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Figure 2. Survival by race (A: black patients; B: white patients) in V-HeFT I.29 Reproduced with permission from Elsevier. HR ¼ hazard ratio; Hyd ¼
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Figure 3. Survival in A-HeFT.24 Reproduced with permission from Massachusetts Medical Society. HR ¼ hazard ratio; Hyd ¼ hydralazine.
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A-HeFT, in which patients had been receiving standard HF
therapy for 3 months, headache and dizziness were signiﬁ-
cantly more frequent in the ISDN plus hydralazine group,
whereas exacerbations of congestive HF (both moderate and
severe) were signiﬁcantly more frequent in the placebo
group.24 Potential adverse events associated with FD
ISDNehydralazine that may require speciﬁc attention
include hypotension and lupus-like syndrome.35Isosorbide Dinitrate and Hydralazine: Individual
Agents Versus Combination Product
Different ISDN and hydralazine preparations were used
for V-HeFT I,27 V-HeFT II,28 and A-HeFT,24 and it has
been postulated that differences in the efﬁcacy results might
be related to pharmacokinetic differences among the drug
formulations. To evaluate the different formulations, a 3-
arm bioequivalence study was conducted in 56 healthy
volunteers who were slow acetylators.36 Subjects wererandomized to receive a single oral dose (10 mg/37.5 mg) of
ISDN tablet plus hydralazine capsule, ISDN tablet plus
hydralazine tablet, or a FD ISDNehydralazine tablet
(10 mg/37.5 mg, which differs from the A-HeFT formula-
tion 20-mg/37.5-mg tablet in current clinical use35). The
maximum concentration (Cmax) and area under the curve
were similar for ISDN in all 3 arms. However, the hydral-
azine tablet produced a lower Cmax (28.2  15.8 ng/ml) and
area under the curve (23.3  15.1 ng$h/ml) compared with
the hydralazine capsule (65.9  53.9 ng/ml; 32.6 
13.4 ng$h/ml) or the FD ISDNehydralazine tablet (51.5 
54.3 ng/ml; 32.6  18.5 ng$h/ml), indicating that the for-
mulations are not bioequivalent. These pharmacokinetic
differences could help explain differences in efﬁcacy be-
tween V-HeFT I and V-HeFT II. However, as these are
pharmacokinetic results from healthy volunteers and no
head-to-head study comparing administration of ISDN and
hydralazine as individual agents versus the FD
ISDNehydralazine tablet has been conducted, no ﬁrm
conclusions can be drawn.
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154 The American Journal of Cardiology (www.ajconline.org)It has been assumed that generic ISDN and hydralazine
are a less expensive alternative than FD ISDNehydralazine
without any disadvantages in terms of compliance. How-
ever, it is reasonable to consider the differences in the
pharmacokinetics among the formulations when prescribing
a treatment regimen. A once- or twice-daily combination
might have both pharmacokinetic and compliance beneﬁts
compared with the current thrice-daily regimen.
Hypertension and HF in Patients of African Ancestry
There is compelling evidence that controlling hyperten-
sion is key to preventing and/or managing overall cardio-
vascular disease morbidity and mortality, including HF.1,37Although epicardial coronary artery disease is the most
common cause of HF in most large clinical trials (predom-
inately in white patients), hypertension is the most common
cause of HF in African-Americans.38,39 In native Africans,
the relation between HF and hypertension was observed in
The Sub-Saharan Africa Survey of Heart Failure, which
enrolled >1,000 patients with acute HF from 9 African
countries over a 3-year period: approximately 50% of the
cases of acute HF were attributed to hypertension.40 Hy-
pertension is often more severe in African-American pa-
tients than in whites, with earlier onset and greater average
systolic and diastolic pressures.41e43 Accordingly, in the
Coronary Artery Risk Development in Young Adults lon-
gitudinal study that evaluated 5,115 subjects from the
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Figure 6. Composite (A) and QOL (B) score changes in A-HeFT by aldosterone synthase 344T/C promoter genotype.52 Reproduced with permission from
Elsevier. Hyd ¼ hydralazine; MLHFQ ¼ Minnesota Living with Heart Failure questionnaire.
Figure 7. Composite score changes in A-HeFT by eNOS exon 7 allele.62 Reproduced with permission from Elsevier. Hyd ¼ hydralazine.
Review/Isosorbide DinitrateeHydralazine and Heart Failure 155United States, black participants were more likely to
develop HF by 50 years of age than whites.44
Patients with moderate or severe hypertension are 2 to 3
times more likely than those with normal BP to develop HF
after 15 years,45 and patients with hypertension are more
likely to have evidence of endothelial damage and
dysfunction compared with those without hypertension.46 A
recent study compared echocardiographic and hemody-
namic ﬁndings between 187 African-American patients with
hypertension and 132 normotensive African-Americans.46
Impaired ﬂow-mediated dilation was found to be inversely
related to BP (r ¼ 0.40, p <0.0001), and a negative as-
sociation between ﬂow-mediated dilation and LV massindex (b ¼ 0.26, p <0.01) was most marked in patients
with concentric LV hypertrophy. Further evaluation with
myocardial contrast echocardiography revealed abnormal
myocardial ﬂow reserve, consistent with microvascular
dysfunction and subendocardial ischemia.46 These data
support the progression from hypertension to HF in African-
American patients. The earlier onset of hypertension and
poorer BP control in many African-Americans may accel-
erate the onset of HF in blacks in the United States
compared with whites and other patients with hyperten-
sion.44 However, the time lag between the development of
hypertension and the onset of HF is still several decades in
African-American patients.
156 The American Journal of Cardiology (www.ajconline.org)Underuse of ISDN and Hydralazine in Eligible Patients
With HF
Despite clinical trial evidence, ISDN and hydralazine
therapy is markedly underused in eligible black patients
with HF and, as a result, a large number of patients are
hospitalized or die from events that could potentially have
been prevented. In the Organized Program to Initiate Life-
saving Treatment in Hospitalized Patients with Heart Failure
(OPTIMIZE-HF) registry of 5,108 black patients hospital-
ized with HF and an EF of <40%, only 4.5% of eligible
patients were prescribed nitrates and hydralazine at hospital
discharge.47 In a study including 17,775 black patients
hospitalized with HF, only 26.4% were treated with nitrates
and hydralazine.48 In the IMPROVE HFSM study in
outpatient cardiology practices treating patients with HF, the
median use of nitrates and hydralazine in black patients with
reduced EF was 0% and the mean was 7.3%.49
According to a meta-analysis, the relative risk reduction
in mortality for ISDN and hydralazine in pivotal, random-
ized clinical trials is 43%, and the number needed to treat
(standardized over 12 months) is 21.50 If the untreated
portion of the current patient population with HF eligible for
treatment with nitrates and hydralazine were treated, >6,650
lives could potentially be saved per year.50 To improve
outcomes, more patients need to be treated according to the
guidelines. There are several ways to facilitate imple-
mentation of HF treatment guidelines, including academic
detailing or educational outreach visits, chart audits with
feedback and the use of reminder systems, and the use of
performance measures based on guidelines. Unfortunately,
there is no performance measure for nitrates and hydralazine
in theAmerican College of Cardiology Foundation/American
Heart Association Task Force on Performance Measures
and the American Medical Association-Physician Con-
sortium for Performance Improvement (ACC/AHA/PCPI)
HF performance measures.51
Physiologic Effects of Hydralazine and Isosorbide
Dinitrate in HF
An echocardiographic subanalysis of the A-HeFT
population by Cohn et al32 determined that FD ISDNe
hydralazine therapy improved LV structure and function.
Echocardiographic data and blood BNP levels were
obtained at baseline and 6 months after randomization.
Measurements of left ventricular ejection fraction (LVEF;
n ¼ 666) and LV internal dimension at end-diastole (n ¼
678) were available at baseline and at 6 months. Although
equivalent at baseline, at 6 months, mean LVEF was
signiﬁcantly increased with FD ISDNehydralazine (p ¼
0.0025 vs placebo) and LV internal dimension at end-
diastole signiﬁcantly decreased (p ¼ 0.0062; Figure 5).
Mean changes in LVEF and LV internal dimension at end-
diastole from baseline to 6 months were also signiﬁcantly
greater with FD ISDNehydralazine (p ¼ 0.0025 and p ¼
0.0062 vs placebo). Mean BNP was signiﬁcantly decreased
after 6 months of therapy with FD ISDNehydralazine (p ¼
0.005 vs placebo), and the mean decrease in BNP at month
6 was also signiﬁcantly greater (p ¼ 0.05), consistent with a
sustained, favorable effect on LV structure and heart
function.Race and the Genetics of HF Therapy
Genetic differences may in part explain the different
response to FD ISDNehydralazine in patients with African
ancestry compared with the general population. At the 6-
month study visit for A-HeFT, 354 study participants
were enrolled in a substudy designed to assess genetic
associations with HF outcomes and response to ISDNe
hydralazine.52 In this Genetic Risk Assessment in Heart
Failure (GRAHF) subgroup, Kaplan-Meier log-rank anal-
ysis was used to examine the relation between event-free
survival and single nucleotide polymorphisms. The
GRAHF subgroup had similar baseline characteristics to the
larger A-HeFT population and similar composite scores
after treatment, although fewer patients in the GRAHF
subgroup died or were hospitalized during the trial. More-
over, alleles and HF outcomes in GRAHF participants (all
of whom were self-identiﬁed black patients) were also
compared with the white cohort from the Global Registry of
Acute Coronary Events (GRACE) study.53 Candidate genes
assessed included aldosterone synthase (CYP11B2) and
endothelial constitutive nitric oxide synthase (eNOS).
The presence of a cytosine (C) at position 344 in the
promoter region of the aldosterone synthase gene is known
to be associated with increased expression of aldosterone
synthase, higher aldosterone synthase activity, and increased
risk of hypertension.54e59 Few of the participants in
GRAHF (6%) had the homozygous CC genotype, although
it was present in 16% of white participants in GRACE. The
TT genotype at position 344, in contrast, was present in
most participants in GRAHF (62%), but only in 30% of
white patients in GRACE.52,53 In GRAHF, patients with the
homozygous TT genotype had signiﬁcantly improved
composite scores and, in particular, improved QOL with
ISDNehydralazine therapy compared with placebo,
whereas ISDNehydralazine therapy did not improve either
measure in patients heterozygous or homozygous for C at
the locus compared with placebo (Figure 6). Thus, in black
patients participating in GRAHF, the TT genotype appeared
to improve response to ISDNehydralazine treatment.
Vascular pathology is associated with an imbalance be-
tween NO and reactive oxygen species levels.14 Multiple
polymorphisms have been identiﬁed in eNOS that can affect
the levels of NO, and at least 3 of these appear to differ by
race.60e62 Evidence supporting a correlation between BP
and eNOS genetic polymorphisms in African-Americans
was initially reported by Li et al60 demonstrating a posi-
tive association between plasma NO level and BP in
normotensive African-Americans who carry the “A” allele
of eNOS. Because the rare “A” allele is signiﬁcantly more
frequent in African-Americans than in other racial or ethnic
groups, this ﬁnding supports a genetic susceptibility to hy-
pertension in African-Americans. Furthermore, Lapu-Bula
et al61 described the association between LV hypertrophy
and the eNOS gene polymorphism, with increased suscep-
tibility to LV hypertrophy in African-Americans who carry
the 894T variant of the eNOS gene and have high-normal
BP or borderline hypertension. For the 84 genotyped
African-American subjects (n ¼ 20 with high-normal BP
[systolic BP 130 to 139 mm Hg, diastolic BP 85 to 89 mm
Hg, or both]; n ¼ 64 matched patients with normal BP
Review/Isosorbide DinitrateeHydralazine and Heart Failure 157[<130/85 mm Hg]), the 894T allelic frequencies (15, 48%)
and G894T genotype distributions were consistent with
equilibrium expectations. LV mass index was signiﬁcantly
higher for the 3 homozygous carriers (TT) of the rare 894T
allele than for the 20 subjects bearing the heterozygous GT
and the 61 subjects bearing the GG variant (124  70 vs
82  24 and 82  19 g/m2, respectively, p <0.05).
Correlation between the eNOS 894T allele and LV mass
index was limited to those subjects with high-normal
BP (r ¼ 0.94, p ¼ 0.03). Therefore, patients with the eNOS
G894T homozygous polymorphismwho had high-normal BP
also had signiﬁcantly greater LV mass, conﬁrming endothe-
lial dysfunction and the potential to progress to HF.61
In addition to underlying susceptibility to hypertension
and endothelial dysfunction, eNOS polymorphisms may
affect response to treatment. In GRACE and GRAHF, both
the homozygous GG polymorphism at position 894 in exon
7 (encoding glutamic acid [Glu] at codon 298) and homo-
zygous TT at locus 786 in the promoter region of the
eNOS gene were far more prevalent in African-Americans,
whereas the homozygous intron 4b was far more common
in white patients than in African-Americans.62,63 These
polymorphisms demonstrate linkage disequilibrium, and
their impact on response to FD ISDNehydralazine cannot
be considered independently of one another. Analysis of the
GRAHF population demonstrated that patients with Glu-Glu
encoded in exon 7 were just as likely to respond to
ISDNehydralazine treatment (based on improved compos-
ite score) as patients with Glu-aspartic acid (Asp) or Asp-
Asp (Figure 7), but they did signiﬁcantly worse when
receiving placebo, particularly in the QOL component.62
Homozygous TT at locus 786 was linked to lower
LVEF before study enrollment, with a trend toward reverse
remodeling in patients with Glu298 polymorphism 6 months
after starting treatment with ISDNehydralazine (change in
LVEF, p ¼ 0.16 vs placebo). These results indicate that
these eNOS polymorphisms may be associated with the
pathophysiology of HF in African-Americans but do not
necessarily affect response to treatment. There may be a
compelling genetic component to the pathophysiology of
HF and potentially the response to therapeutic effects of
ISDNehydralazine in African-Americans. However, these
results must be conﬁrmed in large cohorts of patients.HF and Women: Signiﬁcant Findings from A-HeFT
Women constitute approximately 1/2 of the patients
hospitalized for HF, and deaths from HF among women
contribute 58% of the annual HF-related mortality in the
United States.64,65 Despite this, women have been histori-
cally underrepresented in HF clinical trials. However, in A-
HeFT, women constituted 40% of the enrolled patients (n ¼
420).66 Although HF outcomes in A-HeFT improved in
both men and women, FD ISDNehydralazine tended to
have a greater mortality beneﬁt in the women compared
with the men but without a signiﬁcant treatment interaction
by gender. Among HF clinical trials, A-HeFT provides the
strongest evidence that a therapy appears to be equally
effective in men and women with HF in increasing time to
ﬁrst hospitalization.Treatment Challenges in African-American Patients
With HF
Although the appropriateness of using race to guide
health management decisions is controversial, evidence
from V-HeFT and A-HeFT suggest that self-identiﬁed black
race, possibly affected by often unidentiﬁed polymorphisms,
can affect response to treatment. Challenges faced by cli-
nicians treating patients with HF are multiplied in racial and/
or ethnic minorities and when patients are geographically,
economically, or technologically disadvantaged—the social
determinants of health.67 Diagnosis, follow-up care, and
medication adherence can all suffer when patients do not
have access to reliable transportation or consistent primary
and specialty care and have limited health-care literacy and
educational opportunities. Accordingly, the 2013 American
College of Cardiology Foundation/AHA guideline notes
that a lack of social support is associated with higher hos-
pitalization rates and mortality risk.1
Although there are basic science data and strong clinical
trial evidence for the beneﬁts of FD ISDNehydralazine in
self-described black patients, this guideline-directed medical
therapy remains woefully underused. Additional data, such
as describing the impact of various polymorphisms that may
predict response, or lack thereof, and in blacks and other
racial and/or ethnic groups, need to be developed. Never-
theless, in the interim, the 2013 American College of Car-
diology Foundation/AHA HF guideline for symptomatic HF
in blacks includes the use of FD ISDNehydralazine, if
available. For future considerations, clinicians, researchers,
and public health ofﬁcials must identify and implement
approaches to overcome patient and provider barriers to
appropriate evidence-based care for HF, especially in
African-Americans, to overcome unacceptable disparities in
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